Jump to Main Contents
先端医療開発センター

Home > Organization > Section of Experimental Animals(Kashiwa) > Members > KOGA Yoshikatsu, MD, PhD

KOGA Yoshikatsu, MD, PhD

ykoga.jpg

Official Title

  • Chief, Department of Strategic Programs
  • Head, Section of Experimental Animals
  • Research Scientist, Division of Developmental Therapeutics

Area of research

  • Tumor Diagnostics
  • Tumor Therapeutics
  • Oncology

Keywords

  • Cancer screening
  • Early detection
  • Exfoliated cancer cells
  • Drug delivery system (DDS)
  • Armed antibody
  • PDX models
  • Organoid models
  • Perfusable organoid models
  • Co-clinical trials

Current main research theme

  • Investigation of miRNA test using exfoliated cancer cells
  • Development of novel cancer diagnostic method by highly sensitive protein detection system
  • Preclinical study of antibody/drug conjugated micelle (ADCM)
  • Preclinical study of armed antibody (ADC, RIT, and PIT)
  • PDX models for development of anticancer drugs
  • Organoid models for development of anticancer drugs
  • Co-clinical trials of anticancer drug

Collaborative research themes

  • Early diagnosis of cancer using excretion
  • Preclinical study of armed antibody
  • PDX models and co-clinical trials

Email

ykoga●east.ncc.go.jp(Replace ● to @)

Brief History

  • 1993-1999  Kumamoto University, Medical School, MD
  • 2003-2009  Kumamoto University Graduate School of Medicine, PhD
     
  • 1999-2000  Kumamoto University Hospital, Resident
  • 2000-2002  Miyazaki Prefectural Nobeoka Hospital, Surgeon
  • 2002-2003  Minamata Medical Center Hospital, Surgeon
  • 2003-2006  Kumamoto University Hospital, Surgeon
  • 2006-2009  National Cancer Center Hospital East, Research Resident of Investigative Treatment Division
  • 2009-2011  National Cancer Center Hospital East, Research Fellow of Division of Developmental Therapeutics
  • 2011-         National Cancer Center, Section Head of Experimental Animals
  • 2019-         National Cancer Center, Chief of Department of Strategic Programs

Qualifications

  • National Board of Medicine
  • Japanese Board of Surgery
  • Japanese Board of Gastroenterology
  • Japanese Board of Gastroenterological Endoscopy
  • Japanese Board of Hepatology
  • Japanese Board of Gastrointestinal Cancer Screening

 Major affiliated societies

  • Japan Surgical Society
  • Japanese Society of Gastroenterological Surgery
  • Japanese Society of Gastroenterology
  • Japan Gastroenterological Endoscopy Society
  • Japan Society of Clinical Oncology
  • Japan Society of Hepatology
  • Japanese Cancer Association (Councilor)
  • Japan Society of Drug Delivery System (Councilor)
  • Japanese Society of Gastrointestinal Cancer Screening
  • American Association for Cancer Research

Publications

  1. Tsumura R, Koga Y, Hamada A, Kuwata T, Sasaki H, Doi T, Aikawa K, Ohashi A, Katano I, Ikarashi Y, Ito M, Ochiai A. The report of the use of patient-derived xenograft models in the development of anticancer drugs in Japan. Cancer Sci 111(9):3386-3394, 2020.
  2. Koga Y, Ochiai A. Systematic Review of Patient-Derived Xenograft Models for Preclinical Studies of Anti-Cancer Drugs in Solid Tumors. Cells 8(5):418, 2019.
  3. Yamazaki N, Koga Y, Taniguchi H, Kojima M, Kanemitsu Y, Saito N, Matsumura Y. High expression of miR-181c as a predictive marker of recurrence in stage II colorectal cancer. Oncotarget 8(4):6970-6983, 2017.
  4. Koga Y, Manabe S, Aihara Y, Sato R, Tsumura R, Iwafuji H, Furuya F, Fuchigami H, Fujiwara Y, Hisada Y, Yamamoto Y, Yasunaga M, Matsumura Y. Antitumor effect of anti-tissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts. Int J Cancer 137(6):1457-1466, 2015.
  5. Koga Y, Yasunaga M, Takahashi A, Kuroda J, Moriya Y, Akasu T, Fujita S, Yamamoto S, Baba H, Matsumura Y. MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev Res 3(11):1435-1442, 2010.